Schizophrenia is a chronic and disabling psychiatric condition that affects approximately 1.8 million Americans. Patients with schizophrenia can present with a range of symptoms that are categorized into one of the three symptom domains: positive symptoms (e.g., hallucination, psychosis), negative symptoms (e.g., social withdrawal, apathy, anhedonia), and CIAS (e.g., loss of verbal fluency, memory, attention). Even though schizophrenia is a highly drug-treated indication, treatment is extremely individualized due to patients’ variable response to approved antipsychotic therapies. The Current Treatment Overview summarizes how psychiatrists presently treat schizophrenia across the G7 markets, while the detailed analysis examines U.S. psychiatrists’ current treatment practices and the motivations behind their prescribing decisions.
- Schizophrenia - Current Treatment - Detailed, Expanded Analysis (US)
Author(s): Lisa Cloonan, BA
Lisa joined Decision Resources Group in 2015 as a business insights analyst for the Central Nervous System and Ophthalmology division. In this role, she analyzes the commercial opportunities for pharmacological therapies across the psychiatry space.
Prior to joining Decision Resources Group, Lisa spent 6 years in clinical stroke research at Massachusetts General Hospital. While in the clinical research field, Lisa developed an expertise in neuroimaging analysis, as well as authored and co-authored articles on the influence of white matter hyperintensity burden on stroke risk and recovery. Lisa holds bachelor of arts from Connecticut College, where her course work focused on behavioral neuroscience.